Definitive Healthcare (NASDAQ:DH) Rating Reiterated by Needham & Company LLC

Definitive Healthcare (NASDAQ:DH)‘s stock had its “hold” rating restated by research analysts at Needham & Company LLC in a report issued on Wednesday, Benzinga reports.

Other analysts have also issued research reports about the stock. Robert W. Baird cut their price objective on shares of Definitive Healthcare from $8.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday. Barclays cut their price target on shares of Definitive Healthcare from $11.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Thursday, May 9th. Stifel Nicolaus decreased their price objective on Definitive Healthcare from $11.00 to $9.50 and set a “buy” rating for the company in a report on Wednesday, May 8th. Morgan Stanley lowered Definitive Healthcare from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $11.50 to $9.00 in a report on Wednesday, May 8th. Finally, William Blair restated an “outperform” rating on shares of Definitive Healthcare in a research note on Tuesday, May 14th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $8.45.

Definitive Healthcare Price Performance

DH stock opened at $3.95 on Wednesday. The stock has a 50-day moving average price of $5.48 and a two-hundred day moving average price of $7.09. Definitive Healthcare has a 1 year low of $3.19 and a 1 year high of $11.60. The stock has a market cap of $465.82 million, a PE ratio of -2.26, a price-to-earnings-growth ratio of 3.08 and a beta of 1.30. The company has a current ratio of 2.30, a quick ratio of 2.30 and a debt-to-equity ratio of 0.20.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). The firm had revenue of $63.48 million for the quarter, compared to the consensus estimate of $64.00 million. Definitive Healthcare had a positive return on equity of 0.51% and a negative net margin of 78.16%. Equities analysts forecast that Definitive Healthcare will post 0.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Definitive Healthcare

A number of hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC increased its stake in Definitive Healthcare by 599.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,786 shares of the company’s stock worth $58,000 after acquiring an additional 4,959 shares during the period. Norden Group LLC acquired a new position in shares of Definitive Healthcare in the 1st quarter valued at approximately $83,000. Berry Wealth Group LP bought a new stake in shares of Definitive Healthcare during the 1st quarter worth approximately $99,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Definitive Healthcare by 31.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,292 shares of the company’s stock valued at $116,000 after acquiring an additional 5,083 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in Definitive Healthcare during the first quarter worth $120,000. 98.67% of the stock is owned by institutional investors.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.